Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stivarga in Advanced Previously-Treated Pancreatic Adenocarcinoma
NCT02080260Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jun 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in pancreatic adenocarcinoma (PDAC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of Patients Progression Free and Surviving at 16 Weeks. Started Jun 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02080260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02080260.